ID   MDA-MB-231-MEK-R
AC   CVCL_V403
DR   cancercelllines; CVCL_V403
DR   Cosmic; 1927243
DR   Wikidata; Q54904605
RX   PubMed=22402123;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 20
//
RX   PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010;
RA   Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P.,
RA   Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H.-F., Toy K.,
RA   Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M.,
RA   Moffat J., Belvin M.P., Lackner M.R.;
RT   "ERK inhibition overcomes acquired resistance to MEK inhibitors.";
RL   Mol. Cancer Ther. 11:1143-1154(2012).
//